Dietary Acrylamide and Cancer
This fact sheet provides an overview of data on dietary acrylamide and the risk of developing cancer.
Brain Cancer
BRAIN CANCER ADVISOR
FEATURED CONTENT
-
-
Some Targeted Therapies May Miss the Mark
Ten different drugs continued to kill cancer cells even when their target proteins were removed. -
Clinical Missteps Obscuring a Lung Cancer Diagnosis
Although the rate of cancer misdiagnosis is quite high across malpractice claims, this number does not necessarily correlate with what occurs in clinical practice, an expert warned. -
Immune Response to Isatuximab Correlates With Clinical Response in Patients With Relapsed or Refractory Multiple Myeloma
Could myeloma-associated antibodies could one day serve as biomarkers for predicting which patients will benefit from isatuximab? -
Measurable Residual Disease: The Future of Multiple Myeloma Assessment?
Advances in technology for detecting measurable residual disease (MRD) are also raising questions regarding the role of MRD in managing multiple myeloma.
BRAIN CANCER NEWS
Addition of Bevacizumab to Temozolomide-Based Chemotherapy Increased OR in Children With R/R Neuroblastoma
Bing-Neel Syndrome: Managing Patients With Waldenström Macroglobulinemia Characterized by CNS Involvement
Immunological Profiling of High-Grade Gliomas Reveals Subtypes That Influence Survival
Treatment Reduction in Intermediate-Risk Neuroblastoma Deemed Successful
Outcomes Poor Years After Radiation for Pediatric Glioma Survivors
Want to read more?
Please login or register first to view this content.
